

Hydromorphone vs sufentanil in patient-controlled analgesia for postoperative pain management A meta-analysis

Zhong-Biao Nie, Master^a, Zhi-Hong Li, Ph D^a, Bin Lu, Master^b, Yao-Yao Guo, Master^c, Ran Zhang, Master^{d,*}

Abstract

Background: Patient-controlled analgesia (PCA) is an effective method of postoperative pain, there have been many studies performed that have compared the efficacy of hydromorphone with continuous sufentanil. The purpose of this systematic review is to compare the efficacy and safety of hydromorphone and sufentanil.

Methods: Seven databases were searched for controlled trials to compare the efficacy and safety of hydromorphone and sufentanil. After selecting the studies, extracting the data, and assessing study quality, the meta-analysis was performed on several of the studies with RevMan 5.3.

Results: Thirteen studies comprised of 812 patients were found. The pain intensity of the hydromorphone group was significantly lower than that of the sufentanil group at 12 hours. With no statistical difference at 24 to 48 hours ($MD_{12} = -1.52$, 95% CI [-2.13, -1.97], P < .05). The sedation intensity of the hydromorphone group at 12, 24, and 48 hours were lower than those of the sufentanil group, with no statistical difference ($MD_{12} = -0.03$, 95% CI [-0.18, 0.12], P > .05; $MD_{24} = -0.20$, 95% CI [-0.42, 0.03], P > .05; $MD_{48} = -0.03$, 95% CI [-0.18, 0.11], P > .05. The PCA requests in the hydromorphone group were less than that in the sufentanil group, and there was no significant difference (RR = -0.20, 95% CI [-1.93, 1.53], P > .05). The incidence of adverse events in the hydromorphone group was less than that in the sufentanil group, and there was a statistical difference: (RR = 0.61, 95% CI [-0.47, 0.79], P < .05).

Conclusion: Compared with suferitanil, PCA with hydromorphone was more effective in relieving pain and PCA requests 12, 24, and 48 hours after operation, and significantly reduced the incidence of adverse events, but it did not have an advantage in sedation intensity.

Abbreviations: PCA = patient-controlled analgesia, PCIA = intravenous PCA, RCTs = randomized controlled trials, VAS = Visual Analogue Scale.

Keywords: hydromorphone, meta-analysis, patient-controlled analgesia, sufentanil, systematic review

1. Introduction

Postoperative pain is an acute pain that occurs immediately after surgery, usually lasting no more than 7 days. Effective postoperative analgesia not only alleviates the pain of the patient, but also helps to accelerate the recovery of the disease.^[1]

Editor: Cigdem Sayil.

Received: 17 November 2021 / Received in final form: 18 December 2021 / Accepted: 30 December 2021

http://dx.doi.org/10.1097/MD.000000000028615

Patient-controlled analgesia (PCA) is an effective method of perioperative analgesia, including subcutaneous PCA, epidural PCA, intravenous PCA (PCIA), and peripheral nerve block PCA. Patients can adjust the time and dose of injection of analgesics as needed to meet the analgesic requirements.^[2]

Hydromorphone is a new kind of opioid analgesic. It has the characteristics of strong analgesic effect, long duration, and less adverse events than fentanyl. It is suitable for the treatment of postoperative acute pain, and it would provide long-acting pain relief due to its hydrophilicity and induce fewer adverse events due to its lipophilicity. It is well suited for Enhanced Recovery After Surgery protocols.^[3–7] Sufentanil is a potent opioid analgesic with high selectivity of mu agonists. It has a definite analgesic effect and has the characteristics of stable cardiovascular function, and it is a cheap synthetic opioid with a high therapeutic index and a quick response, is an attractive drug for postoperative pain.^[8–12] In recent years, many clinical studies on the efficacy and safety of these 2 drugs for PCA have been made, however, these results were controversial. Therefore, we made the systematic review and meta-analysis comparison of the effects between the 2 drugs.

2. Methods

Data collection and analysis were performed by the best practice Cochrane Association guidelines^[13] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews.^[14] The ethical approval and

The authors have no conflicts of interests to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

^a Shanxi Bethune Hospital, Pharmaceutical Department, Taiyuan, China, ^b Shanxi Bethune Hospital, Anesthesiology Department, Taiyuan, China, ^c Shanxi Bethune Hospital, Pain Department, Taiyuan, China, ^d Affiliated Hospital of Shanxi University of Traditional Chinese Medicine, Nephrology Department, Taiyuan, China.

^{*} Correspondence: Ran Zhang, Affiliated Hospital of Shanxi University of Chinese Medicine, Nephrology Department, Taiyuan 030036, China (e-mail: 115462888@qq.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Nie ZB, Li ZH, Lu B, Guo YY, Zhang R. Hydromorphone vs sufentanil in patient-controlled analgesia for postoperative pain management: a meta-analysis. Medicine 2022;101:3(e28615).

informed consent were unnecessary since the meta-analysis was aimed to summarize the previous studies.

We sought randomized controlled trials (RCTs) that the clinical effects of hydromorphone and sufentanil for PCA after an operation. Reports were identified by Pub Med, EMBASE TM, Cochrane Central Register of Controlled Trials, and 3 Chinese databases, including the Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and Wan fang Data using the following search terms as keywords and text words: "hydromorphone", "sufentanil", "PCA" "patient-controlled analgesia," "self-administered," "pain," "analgesia," "postoperative," and "surgery." Alternative spellings of the search terms were also used. Without restriction to regions, publication types, or languages confining the search to studies published between inception and July 2, 2018.

2.1. Inclusion and exclusion criteria

Inclusion criteria were:

- 1. RCTs;
- 2. adult surgical patients receiving postoperative PCA;
- 3. the use of opioid for a PCA strategy; and
- 4. postoperative pain-related outcomes and PCA-related adverse events.

Exclusion criteria were:

- 1. hydromorphone was not compared with sufentanil;
- 2. animal trials, reviews, and other genres, repeated publication;
- only abstract and lack of full text, or full text does not provide sufficient raw data;
- 4. abstracts of scientific meetings, unpublished observations, and correspondence.

Two reviewers identified all studies that appeared to fit the inclusion criteria for the full review. Two reviewers independently selected studies for inclusion in the review. Any disagreements were referred to a third reviewer. If data were reported in a format that did not allow inclusion in the meta-analysis, we contacted the authors and asked them to release data. We identified a total of 13 RCTs. The study characteristics for each included trial are shown in Table 1.

Table 1

Characteristics of included trials and the PCA protocols.

All studies comparing hydromorphone to sufentanil for PCA were included. The outcome were: pain intensity, as measured by the Visual Analogue Scale (VAS) score, VAS is the most common measurement to assess pain intensity. It is scored on a range of either 0 to 10(0 = no pain, 10 = worst pain). Sedation intensity, as measured by the Ramsay score at the 12/24/48 hours after operation; PCA requests for analgesia, adverse events of patients. We also conducted subgroup analyses to explore the various types of PCAs on the incidence of postoperative pain management. We separated PCIA and epidural PCA for analysis.

2.3. Statistical analyses

Results that were pooled from the included studies were metaanalyzed. For continuous data, a Mantel-Haenszel Chi-Squared test was used and expressed as the mean difference with 95% CI, and for dichotomous data an inverse variance was used and expressed as risk ratio with 95% CI. In both cases P < .05 was considered significant. Heterogeneity was analyzed using a Chi-Squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I^2 test. I^2 values of 25%, 50%, and 75% correspond to low, medium, and high levels of heterogeneity. A fixed-effect model was used unless statistically significant high heterogeneity $(I^2 > 75\%)$ was considered as significantly high heterogeneity) existed between studies. A random-effects model was employed if heterogeneity existed. An assessment of the methodological quality of the included studies into the meta-analysis was conducted in line with the Cochrane handbook.^[28,29] Review Manager (Rev Man 5.3) was used to plot the quality assessment.

3. Results

3.1. Study selection

A total of 64 citations were identified for eligibility through the systematic literature search. After exclusion of duplicate publications and full-text review of the relevant studies. A total of 13 cohort studies encompassing 812(411 patients were hydromorphone group and 401 patients were sufentanil group)

				Intervention n	neasures		
Reference	Analgesic mode	Sample size	ASA classification	hydromorphone group	sufentanil group	Loading dose/ basal infusion /bolus dose/lockout interval	Measurement index [*]
ZF Yu 2015 I–IV ^[15]	PCSA	40/40	I—II	0.06–0.09 mg/kg	150 µg	$5 \text{ mL/2 mL} \times \text{h}^{-1}$ /1 mL $\times \text{time}^{-1}$ /10 min	A, P
LH Liu 2015 ^[16]	PCEA	35/35	I—II	150 µg	100 µg	$5 \text{ mL/2 mL} \times \text{h}^{-1}$ /1 mL $\times \text{time}^{-1}$ /10 min	V, A, R, P
XH Sun 2015 I~II ^[17]	PCIA	50/50	I—II	2/4 mg	50 µg	none/2 mL \times h ⁻¹ /0.5 mL \times time ⁻¹ /15min	V, A, R, P
YW Cui 2015 ^[18]	PCIA	30/30	I—II	8 mg	100 µg	$5 \text{ mL/4mL} \times \text{h}^{-1}/2 \text{ mL} \times \text{time}^{-1}/30 \text{ min}$	V, A, R, P
XF Cao 2017 ^[19]	PCIA	30/30	I—II	120–140 µg/kg	2-3 µg/kg	none/2 mL \times h ⁻¹ /2 mL \times time ⁻¹ /15min	V, A, P
XZ Qi 2018 ^[20]	PCIA	30/30	I—II	200 µg/kg	2 μg/kg	$5 \text{ mL/2 mL} \times \text{h}^{-1}/\text{2ml} \times \text{time}^{-1}/15 \text{min}$	V, A, P
ZY Zhao 2014 ^[21]	PCIA	25/25	I—II	100 µg/kg	3μg/kg	none/2 mL \times h ⁻¹ /0.5 mL \times time ⁻¹ /15 min	A, R, P
R Han 2017 ^[22]	PCIA	31/31	I—II	8 mg	100 µg	-	V, P
HG Wang 2014 ^[23]	PCIA	30/30	I—II	96 µg/kg	2.4 µg/kg	$2(0.15)^{**} \mu g \times kg^{-1}/2 \text{ mL} \times time^{-1}/2 \text{ mL} \times time^{-1}/20 \text{ min}$	V, R, P
MX Su 2017 ^[24]	PCEA	30/30	I—II	7 mg	150 μց	$5 \text{ mL/2 mL} \times \text{h}^{-1}/\text{2 mL} \times \text{time}^{-1}/\text{30 min}$	V, P
FM Yang 2016 ^[25]	PCIA	40/40	I—II	10 mg	100 µg	none/2 mL \times h ⁻¹ /2 mL \times time ⁻¹ /20min	V, R, P
XC Bian 2017 I-III ^[26]	PCIA	20/20	I—II	50–150 μg/kg	100 µg	none/2 mL \times h ⁻¹ /0.5 mL \times time ⁻¹ /15 min	V, R, P
Y Tao 2015 I–II ^[27]	PCEA	20/20		25/50 µg/kg	1 μg/kg	none/2 mL \times h ⁻¹ /0.5mL \times time ⁻¹ /15min	V, A, R, P

*A = PCA request; P = adverse events; R = Ramsay score; V = VAS score. **: the loading dose of hydromorphone and sufentanil respectively.



Figure 1. Flow diagram of study selection and identification.

individuals were included in the quantitative synthesis (Fig. 1). All the included studies were randomized controlled trials. All of the studies were from centers in China and all studies were singlecenter studies.

3.2. Risk of bias assessment

The details of methodologic quality are shown in Figure 2. Ten studies^[15–17,19–21,23–26] did not describe the details of random



sequence generation. All studies had unclear risks of bias due to blinding of outcome assessment, incomplete outcome data, and selective reporting.

3.3. Meta-analysis results

3.3.1. Postoperative pain intensity. Eleven studies^[16–20,22–27] provided VAS score data for patients at different time points 12, 24, and 48 hours after surgery. Statistical heterogeneity was found among the studies (P < .001, $I^2 = 99\%$). A random-effect model was used to analyze the data. Meta-analysis showed that pain score of the hydromorphone group was significantly lower than that of the sufentanil group at 12 hours. With no statistical difference at 24 to 48 hours (Weighted mean difference [MD] was MD₁₂=-1.52, 95% CI [-2.13, -1.97], P < .05; MD₂₄=-0.10, 95% CI [-0.81, 0.06], P > .05; MD₄₈=-0.68, 95% CI [-1.85, 0.49], P > .05), see Figures 3–5.

3.3.2. Postoperative sedation intensity. Eight studies^[16–18,21,23,25–27] provided Ramsay score data for patients at different time points 12 to 24 hours after surgery. Statistical heterogeneity was found among the studies (P < .001, $I^2 = 75\%$; 90%; 83%). Random effect model was used to analyze the data. Meta-analysis showed that the sedation scores of the hydromorphone group at 12 to 24 hours were lower than those of the sufentanil group, with no statistical difference. (MD₁₂=-0.05, 95% CI [-0.23, 0.12], P > .05; MD₂₄=-0.22, 95% CI [-0.47, 0.03], P > .05), see the Figures 6 and 7.

3.3.3. PCA requests for analgesia. Eight studies^[15–21,27] reported the number of PCA requests. Statistical heterogeneity (P < .001, $I^2 = 99\%$) was found among the studies. Random effect model was used to analyze the results. Meta-analysis showed that the number of PCA requests in the hydromorphone group was less than that in the sufentanil group, and there was no significant difference (RR=-0.20, 95% CI [-1.93,1.53], P > .05), see the Figure 8.

3.3.4. Postoperative adverse reaction rate. Thirteen studies^[15-27] reported the incidence of postoperative adverse events. The main adverse events include postoperative nausea vomiting (PONV), somnolence, pruritus. Therefore, we set up 3 subgroups for analysis. Statistical heterogeneity was found among the studies (P < .001, $I^2 = 9\%$). Random effect model was used to analyze the incidence of postoperative adverse events. Meta-analysis showed that the incidence of adverse events in the hydromorphone group was less than that in the sufentanil group, and there was a statistical difference (RR=0.61, 95% CI [0.47,0.79], P < .05), see Figure 9.

3.3.5. *Publication bias.* The funnel plot was used to analyze the incidence of adverse events. As a result, the distribution of the inverted funnel plot is asymmetrical, suggesting that there may be large publication bias and clinical heterogeneity in the included literature, see Figure 10.

4. Discussion

Patient-controlled analgesia pump, which is characterized by high efficiency, no blind zone for analgesia, and stable blood concentration, has been widely used in postoperative rapid analgesia. At present, sufentanil is the representative used in intravenous analgesia in a clinic,^[2,30] characterized by obvious analgesic effect and long duration of action. However, it always causes vertigo, pruritus, nausea, and vomiting. Hydromorphone, as a novel powerful opioid with a clear analgesic effect, has been reported both at home and abroad.^[7] A meta-analysis of Felden

	Hydro	morph	one	Sut	fentan	il		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.1.1 PCIA 12h									
FM Yang 2016	1.2	0.45	40	1.36	0.92	40	2.6%	-0.16 [-0.48, 0.16]	
HG Wang 2014	1.3	0.6	30	1.4	0.5	30	3.4%	-0.10 [-0.38, 0.18]	-
MX Su 2017	0.7	0.2	30	2.89	0.15	30	33.1%	-2.19 [-2.28, -2.10]	
R Han 2017	2.44	1.51	31	2.32	1.65	31	0.4%	0.12 [-0.67, 0.91]	
XC Bian 2017 I	4.62	1.01	20	3.42	0.43	20	1.1%	1.20 [0.72, 1.68]	
XC Bian 2017III	3.12	0.71	20	3.42	0.43	20	2.0%	-0.30 [-0.66, 0.06]	
XC Bian2017II	3.51	0.58	20	3.42	0.43	20	2.6%	0.09 [-0.23, 0.41]	+
XF Cao 2017	2.67	0.55	30	2.8	0.41	30	4.4%	-0.13 [-0.38, 0.12]	
XH Sun 2015 I	4.29	0.81	50	2.17	0.68	50	3.1%	2.12 [1.83, 2.41]	
XH Sun 2015II	2.41	0.97	50	2.17	0.68	50	2.5%	0.24 [-0.09, 0.57]	
YW Cui 2015	1.16	0.41	30	1.35	0.75	30	2.8%	-0.19 [-0.50, 0.12]	
Subtotal (95% CI)			351			351	58.1%	-1.14 [-1.21, -1.07]	
Heterogeneity: Chi2 =	= 1443.29	, df = 10	0 (P < 0	.00001)	; 12 = 9	9%			
Test for overall effect	Z = 33.0	6 (P < (0.00001)					
1.1.2 PCEA 12h									
LH Liu 2015	0.71	0.21	35	2.88	0.13	35	39.5%	-2.17 [-2.25, -2.09]	
Y Tao 2015 1	1,96	0.72	20	1.99	0.82	20	1.2%	-0.03 [-0.51, 0.45]	
Y Tao 2015II	1.92	0.67	20	1.99	0.82	20	1.2%	-0.07 [-0.53, 0.39]	
Subtotal (95% CI)			75			75	41.9%	-2.05 [-2.13, -1.97]	•
Heterogeneity: Chi# =	= 146.72,	df = 2 (P < 0.00	0001); P	= 999	6			
Test for overall effect	Z= 50.5	5 (P < 0	0.00001)					
Total (95% CI)			426			426	100.0%	-1.52 [-1.57, -1.47]	1
Heterogeneity: Chi#:	1882.96	, df = 1:	3 (P < 0	.00001)); I ² = 9	9%		-	
Test for overall effect	Z= 57.9	2 (P < 0	0.00001)					-2 -1 0 1 Z
Test for subaroup di	fferences	Chi#=	292.95	df = 1	(P < 0.	00001	I"= 99.7	96	Hydromorphone Sulentanii
F	iaure 3. ⁻	The pair	n intens	sitv anal	vsis of	hvdror	norphone	vs sufentanil for PCA u	p to postoperative 12 hours.

	Hydro	morph	one	Sut	entan	it		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 PCIA 24h				1011111				A CONTRACTOR STOLEN	
FM Yang 2016	0.88	0.62	40	1.22	0.76	40	7.2%	-0.34 [-0.64, -0.04]	-
HG Wang 2014	0.6	0.2	30	0.5	0.3	30	7.3%	0.10 [-0.03, 0.23]	-
R Han 2017	1.77	1.68	31	1.79	1.56	31	6.7%	-0.02 [-0.83, 0.79]	+
XC Bian 2017 I	3.97	1.44	20	2.06	0.24	20	6.9%	1.91 [1.27, 2.55]	-
XC Bian 2017III	1.89	0.24	20	2.06	0.24	20	7.3%	-0.17 [-0.32, -0.02]	-
XC Bian2017II	2.01	0.15	20	2.06	0.24	20	7.3%	-0.05 [-0.17, 0.07]	+
XF Cao 2017	2.27	0.52	30	2.4	0.56	30	7.2%	-0.13 [-0.40, 0.14]	+
XH Sun 2015 I	3.67	1.35	50	2.06	1.1	50	7.1%	1.61 [1.13, 2.09]	-
XH Sun 2015II	2.16	0.76	50	2.06	1.1	50	7.2%	0.10 [-0.27, 0.47]	+
XZ QI 2018	1.8	0.4	30	3.4	0.5	30	7.3%	-1.60 [-1.83, -1.37]	-
YW Cui 2015	0.95	0.83	30	1.15	0.49	30	7.2%	-0.20 [-0.54, 0.14]	+
Subtotal (95% CI)			351			351	78.6%	0.06 [-0.30, 0.43]	•
Heterogeneity: Tau* =	= 0.34; CH	ni# = 26	4.71, dt	(= 10 (P	< 0.0	3001); 1	*= 96%		
Test for overall effect	Z=0.34	(P = 0.	74)			1.24.554			
1.3.2 PCEA 24h									
LH Liu 2015	0.52	0.13	35	2.86	0.18	35	7.3%	-2.34 [-2.41, -2.27]	
Y Tao 2015 I	1.93	0.82	20	1.99	0.82	20	7.0%	-0.06 [-0.57, 0.45]	+
Y Tao 2015II	1.9	0.63	20	1.99	0.82	20	7.1%	-0.09 [-0.54, 0.36]	+
Subtotal (95% CI)			75			75	21.4%	-0.84 [-2.65, 0.96]	-
Heterogeneity: Tau ² =	= 2.50; CH	ni= 16	4.23, dt	= 2 (P	0.00	001); P	= 99%		
Test for overall effect	Z = 0.91	(P = 0.	36)	1 A.A.					
Total (95% CI)			426			426	100.0%	-0.10 [-0.81, 0.60]	+
Heterogeneity: Tau* =	= 1.78; CH	ni= 22	53.55,	df=13(P < 0.0	00001);	I= 99%	di anti anti anti anti anti	
Test for overall effect	Z=0.29	(P = 0.	78)						-4 -2 U Z 4
Test for subaroup dif	Terences	Chi ² =	0.93. d	f=1 (P	= 0.34), $ ^{2} = 0$	%		nydromorphone sufentanii

Figure 4. The pain intensity analysis of hydromorphone vs sufentanil for PCA up to postoperative 24 hours.

	Hydro	morph	one	Su	fentan	it		Mean Difference		Mean	Differen	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rat	ndom, 95	% CI	
1.4.1 PCIA 48h													
HG Wang 2014	0.2	0.3	30	0.2	0.4	30	20.1%	0.00 [-0.18, 0.18]			+		
XF Cao 2017	1.6	0.81	30	1.7	0.88	30	19.7%	-0.10 [-0.53, 0.33]			+		
XZ Qi 2018	1.3	0.4	30	2.1	0.5	30	20.1%	-0.80 [-1.03, -0.57]		-	-		
YW Cui 2015	1.23	0.72	30	1.45	0.76	30	19.8%	-0.22 [-0.59, 0.15]			-		
Subtotal (95% CI)			120			120	79.8%	-0.29 [-0.72, 0.15]			•		
Heterogeneity: Tau ² =	0.17; Ch	ni# = 29.	97, df=	: 3 (P <	0.000	01); I#=	90%	(2014) (17 6) (27 8)					
Test for overall effect	Z=1.28	(P = 0.)	20)										
1.4.2 PCEA 48h													
LH Liu 2015	0.51	0.23	35	2.75	0.11	35	20.2%	-2.24 [-2.32, -2.16]					
Subtotal (95% CI)			35			35	20.2%	-2.24 [-2.32, -2.16]					
Heterogeneity: Not ap	plicable							12. 1. 2					
Test for overall effect	Z= 51.9	8 (P < 0	0.00001)									
Total (95% CI)			155			155	100.0%	-0.68 [-1.85, 0.49]					
Heterogeneity: Tau* =	= 1.75; CH	ni# = 67	3.11, dt	= 4 (P	< 0.00	001); F	= 99%	-	+	-	-	-	-
Test for overall effect	Z=1.14	(P = 0.1)	26)				1000		-4	-2	0	Z	4
Test for subaroup diff	ferences	Chi ² =	73.75.	df = 1 (F	< 0.0	0001).	1= 98.69	6	Hyd	romorpho	ne sufe	ntanii	
Figu	ro 5 Th	a nain i	intoneit	v analyc	vic of h	vdrom	orphono v	orque sufontanil for PCA	un to pr	etoporativ	o 18 hour	·e	

^[4] has shown that the clinical efficacy of hydromorphone in acute pain is slightly superior to morphine. There are many studies on the clinical efficacy of hydromorphone and sufentanil in PCA, but evidence-based medicine is lacking for their efficacy and safety.

Our meta-analysis showed that compared with sufentanil, hydromorphone can significantly reduce postoperative pain for 12 hours, there was no significant difference in sedation, and PCA requests, but the incidence of adverse events in the hydromorphone group was significantly better than that in the sufentanil group, especially in PONV and somnolence. It may be due to the hydrophilicity of hydromorphone, which can provide long-lasting analgesic effects and cause fewer adverse events. $^{[4,32]}$

Although some studies have found that basal infusion of sufentanil PCIA can effectively relieve pain with few adverse events, ^[33] American Pain Society recommends against routine basal infusion of opioids with i.v. PCA in opioid-naive adults. ^[34] Therefore, adverse events such as PONV in the included studies may be related to the basal infusion.

Our study revealed an article by Hua,^[31]in which the postoperative VAS score was higher than 10 (the highest score

	hydron	morphe	one	suf	entani	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
4.1.1 PCIA 12h									
FM Yang 2016	1.81	0.55	40	2.57	0.77	40	9.3%	-0.76 [-1.05, -0.47]	-
XC Bian 2017 1	1.81	1.07	20	1.89	0.44	20	6.1%	-0.08 [-0.59, 0.43]	
XC Bian 2017III	2.49	0.71	20	1.89	0.44	20	8.1%	0.60 [0.23, 0.97]	
XC Bian2017II	1.86	0.59	20	1.89	0.44	20	8.8%	-0.03 [-0.35, 0.29]	+
XH Sun 2015 I	2.01	1.13	50	2.23	0.85	50	7.7%	-0.22 [-0.61, 0.17]	
XH Sun 2015II	2.01	0.31	50	2.23	0.85	50	10.0%	-0.22 [-0.47, 0.03]	+
YW Cui 2015	2.5	0.51	30	2.4	0.51	30	9.9%	0.10[-0.16, 0.36]	+
ZY Zhao 2014	2.33	0.42	25	2.45	0.53	25	9.7%	-0.12 [-0.39, 0.15]	+
Subtotal (95% CI)			255			255	69.5%	-0.10 [-0.35, 0.16]	•
4.1.2 PCEA 12h	2=0.75	(P = 0,	40)						
LH Liu 2015	0.73	0.32	35	0.81	0.25	35	11.7%	-0.08 [-0.21, 0.05]	-
Y Tao 2015 I	2.24	0.38	20	2.15	0.52	20	9.5%	0.09[-0.19, 0.37]	+
Y Tao 2015II	2.36	0.41	20	2.15	0.52	20	9.3%	0.21 1-0.08, 0.501	+-
Subtotal (95% CI)			75		0.00	75	30.5%	0.03 [-0.14, 0.21]	•
Heterogeneity: Tau*:	= 0.01; Ch	ni= 3.7	3. df=	2(P = 0)	15); P	= 46%			
Test for overall effect	Z = 0.38	(P = 0.	70)						
Total (95% CI)			330			330	100.0%	-0.05 [-0.23, 0.12]	• • • •
Heterogeneity: Tau*:	= 0.06; Ct	n ² = 42	76, df=	= 10 (P	< 0.000	001); P	= 77%		+ + + + +
Test for overall effect	Z=0.58	(P = 0.	56)	1000					-4 -Z U Z 4
Test for subgroup dit	ferences	Chi ² =	0.69 d	f=1 (P	= 0.41) F= 0	96		sutentanii hydromorphone

Figure 6. The Ramsay intensity analysis of hydromorphone versus sufentanil for PCA up to postoperative 12 hours.

	hydro	morphe	one	suf	entan	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.2.1 PCIA 24h				10000					
FM Yang 2016	1.78	0.48	40	2.72	0.83	40	9.0%	-0.94 [-1.24, -0.64]	
HG Wang 2014	1	0	30	1	0	30		Not estimable	
XC Bian 2017 I	1.91	1.04	20	2.01	0.23	20	7.6%	-0.10 [-0.57, 0.37]	
XC Bian 2017III	2.06	0.74	20	2.01	0.23	20	8.7%	0.05 [-0.29, 0.39]	
XC Bian2017II	1.98	0.15	20	2.01	0.23	20	10.1%	-0.03 [-0.15, 0.09]	+
XH Sun 2015 I	1.68	0.75	50	2.04	1.02	50	8.6%	-0.36 [-0.71, -0.01]	
XH Sun 2015II	2.21	0.28	50	2.04	1.02	50	9.0%	0.17 [-0.12, 0.46]	
YW Cui 2015	1.15	0.49	30	2.43	0.51	30	9.3%	-1.28 [-1.53, -1.03]	
ZY Zhao 2014	2.12	0.38	25	2.26	0.42	25	9.5%	-0.14 [-0.36, 0.08]	-++
Subtotal (95% CI)			285			285	71.8%	-0.33 [-0.69, 0.03]	•
Heterogeneity: Tau* =	= 0.24; Ch	ni [#] = 10	9.76, dt	= 7 (P	< 0.000	001); F	= 94%		
Test for overall effect	Z=1.82	(P = 0.	07)						
4.2.2 PCEA 24h									
LH Liu 2015	0.72	0.25	35	0.8	0.31	35	10.0%	-0.08 [-0.21, 0.05]	-
Y Tao 2015 I	2.24	0.38	20	2.15	0.52	20	9.1%	0.09[-0.19, 0.37]	
Y Tao 2015II	2.36	0.41	20	2.15	0.52	20	9.1%	0.21 [-0.08, 0.50]	+
Subtotal (95% CI)			75			75	28.2%	0.03 [-0.14, 0.21]	+
Heterogeneity: Tau* =	= 0.01; Ch	hi ² = 3.7	7, df=	2(P = 0	15); P	= 47%			
Test for overall effect	Z = 0.38	(P=0.	71)						
Total (95% CI)			360			360	100.0%	-0.22 [-0.47, 0.03]	•
Heterogeneity: Tau* =	= 0.16; CH	n#= 12	4.53, dt	(= 10 (P	< 0.00	0001);1	= 92%		
Test for overall effect	Z=1.73	(P = 0.	(80						-2 -1 0 1 2
Test for subaroup dif	ferences	Chi ² =	3.22 d	f=1 (P	= 0.07). = 6	8.9%		sutentanii hydromorphone
Figure	e 7 . The	Ramsa	v intens	sitv anal	vsis of	hvdroi	morphone	e versus sufentanil for F	PCA up to postoperative 24 hours

is 10). Therefore, we contacted the author but did not receive any reply, so we excluded this article.

There are multiple-dose comparative studies in some articles.^[15,17,26,27] We analyzed separate experiments with different doses.

There are shortcomings and limitations in this study:

- 1. This systematic review included 13 studies, all of which were Chinese articles. Although we searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and WHO International Clinical Trials Registry Platform, we found few English language studies.
- 2. There were some differences in the dosage of each study, and the loading dose/basal infusion/locking time of PCA drugs included in the study were also different.

The literature reveals that, between 1996 and 1999, 25 sedation assessment tools were published, of which 3 have been rigorously tested for validity and reliability in adults: the motor activity assessment scale, the Ramsay sedation scale and the sedation agitation scale (SAS) Their study can be criticized, however, only the Ramsay scale had been validated adequately for use in the critical care environment, so more studies have chosen Ramsay scale.^[35]

	Hydro	morph	one	Suf	entan	ii ii		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
LH Liu 2015	0.72	0.25	35	0.8	0.31	35	7.9%	-0.08 [-0.21, 0.05]	
XF Cao 2017	3.53	2.34	30	4.57	4.03	30	7.4%	-1.04 [-2.71, 0.63]	
XH Sun 2015 I	16.8	3.6	50	2.06	1.1	50	7.7%	14.74 [13.70, 15.78]	
KH Sun 2015II	7.8	2.1	50	2.06	1.1	50	7.8%	5.74 [5.08, 6.40]	-
XZ QI 2018	1.7	0.6	30	2.7	0.7	30	7.9%	-1.00 [-1.33, -0.67]	-
Y Tao 2015 I	3.12	1.45	20	6.85	3.28	20	7.4%	-3.73 [-5.30, -2.16]	
Y Tao 2015II	3.05	1.32	20	6.85	3.28	20	7.5%	-3.80 [-5.35, -2.25]	
YW Cui 2015	3.21	0.81	30	3.3	1.15	30	7.9%	-0.09 [-0.59, 0.41]	+
ZF Yu 2015 I	9.1	1.6	40	8.9	1.7	40	7.8%	0.20 [-0.52, 0.92]	+
ZF Yu 2015II	8.3	1.3	40	8.9	1.7	40	7.8%	-0.60 [-1.26, 0.06]	-
ZF Yu 2015III	3.7	1.8	40	8.9	1.7	40	7.8%	-5.20 [-5.97, -4.43]	-
ZF Yu 2015IV	3	1.4	40	8.9	1.7	40	7.8%	-5.90 [-6.58, -5.22]	+
ZY Zhao 2014	6.08	3.01	25	8.28	4.21	25	7.2%	-2.20 [-4.23, -0.17]	
Total (95% CI)			450			450	100.0%	-0.20 [-1.93, 1.53]	+
Heterogeneity: Tau* =	9.84; CH	ni ² = 16	05.56.0	df = 12 (P < 0.	00001);	1= 99%		
Test for overall effect	Z=0.23	(P = 0.	82)	27 Juni 6-31					-10 -5 0 5 10 Favours Hydromorphone Favours Sufentanil

Figure 8. The PCA requests analysis of hydromorphone versus sufentanil for PCA up to postoperative 12/24/48 hours.

Charles out Carbonnesson	Hydromory	phone	Sufert	and .		Filsk Flatio	Pisik Ratio
Service of Strengt man	Events	Tetal	Events.	Total	Weight	M.H. Fixed, 95% (J	M.H. Forest, 95% CI
G.I.TPONY		40		140		0.20.00.00.4.200	
HO Wang 2014	2	30	- 2	- 55	0.7%	2 00 10 19 20 901	
LH LN 2015	3	35	2	25	1.4%	1.50 10 27. 8 4 31	
MCK III 2017	2	20	1	30	0.7%	2 00 10 19, 20 900	
R Hain 2017	1	31	6	21	4.2%	0 17 (0.02, 1.30)	
30C Bian 20171	9	20	2	20	1.4%	0.50 (0.05, 5.08)	
XC Bian 201702	2	20	2	20	1.4%	1.00 (0 16, 6.42)	
NC Blan201711	.5	20	2	20	1.4%	2 50 [0.55, 11 41]	
39 Cae 2017	0	30	12	30	8.8%	0.04 (0.00, 0.05)	
304 040 2015 1		50	1	20	215	1 23 23 24 4 4 10	
37 05 2010		30	- 1	- 30	214	0.3330.04.3.03	
V Tan 2015 1	1	20	1	26	0.7%	1 00 10 07, 14 901	
Y Tao 201511		20	1	20	0.7%	8 00 11 10, 58 19	
WW Cui 2015	1	30	5	20	4.2%	0.13(0.02, 1.06)	
ZF 1/4 20151	0	40	2	40	1.5%	0.20 (0.01, 4.04)	
2F 11v 20151	0	40	2	40	1.0%	0.20 (0.01, 4.04)	
ZF YV 201500	0	40	2	40	1.8%	0.2010.01.4.04	
29 114 201509	2	40	- 2	40	1.4%	1.50 (0.26, 0.50)	
ZY 2190 2014	,	25		25	2.1%	0.33 [3:04, 2:99]	•
Subtorial (PS-5-C.0	-			831	46.011	over the external	
Materiana and Chille	20.00 48-1	0.00-0	120 0 - 1	29			
Test for overall effect	Z=253(P)	0.011	and the state				
and a second surger	- starter						
6.1.2 somolence							
FM Yang 2016	1	40	1	.40	2.1%	0 33 (0 04, 3 07)	
HO-Wang 2014	0	30	0	20		Not estimable	
LH Liu 2015	2	35	3	35	2.1%	0.67 (0.12, 3.75)	
MOX 844 2017	0	30	0	20		Not estimable	
R Han 2017	0	31		31		Not estmable	
XC Bian 2017 I	0	20	:	- 20		Not estimable	
NO BIAN 201718	0	20		- 55		Not estimate	
35 Bian/017B		20		- 55	5.00	0.33-03-10-1-141	
NH Bun 2016 I		50		- 65	2.6%	0.1410.01.270	
XH Bun 2015II	3	50	i i	50	21%	1.0010 21, 4 721	
X2 05 2018	0	30	0	20		hast waternable	
Y Tao 2015 I	2	20	1	20	0.7%	2 00 (0 20, 20 33)	
V Tao 2015II	2	20	1	20	0.7%	3.00 (0.34, 26, 45)	
WV Cui 2015	0	30	0	20		Not estimable	
29 Yu 20151	0	40		80	4.0%	0.09 (0.00, 1.32)	
ZF 11s 20161	0	40	6	40	4.8%	0.08 (0.00, 1.32)	
25 1/4 201500	0	40	6	40	4.5%	0.0830.00,1.323	
2F Yo 20168V		40		40	4.2%	1.33 (0.51, 3.49)	
ZY Zhao 2014	1	25	1	25	0.7%	1.00 (0.07, 15.1.2)	
Subtorial (dave cit)		641		631	35.4%	0.20 10/25 0/141	
Helenicensily Chills	15.34 10 - 1	1 (P = 0	171 1-1	10.00			
Test for overall effect	Z= 2.95 (P	0.003)					
6.1.3 prosition							
FM Vang 2016	1	40	3	40	21%	0.33 (0.04, 3.07)	
HG Wang 2014	0	30		30		Not estimable	
LH LN 2015	2	35		35	0.7%	2.00 (0.19, 21.06)	
MK 9u 2017	1	30		39	0.7%	1.00 (0.07, 15.26)	
R Han 2017	0	24	0	21		Not estimable	
NC Bian 20171	0	20		20	1.1%	0 33 92 01, 7 72	
20. Ellari 201710	0	20		20	1.1%	2 00 10 20 20 20 20	
with Shines Series 2010		20		20	0.16	2 00 (0.20, 20 33)	
300 Bian2017II				10		had entire able	
300 Blan 201711 30F Cast 2017 304 Sup 2015 F	0	-10		1000		test a settlarie	
300 Blan20178 30F Cao 2017 304 Sun 2015 I 304 Sun 20158	0	50	0	50		Not extraction	
302 Blan 20178 307 Cao 2017 304 Sun 2015 1 304 Sun 2015 1 304 Sun 20158 304 Sun 20158	0	50 50 30	0	50		Not estimable	
xiC Bian20178 xF Cao 2017 xH Sun 2015 I xH Sun 20151 xZ GI 2018 V Tao 2015 1	000000000000000000000000000000000000000	30 50 50 30 20	000	50 30 20	0.7%	Not estimable Not estimable 1.00 (0.07, 14.90)	
302 Blan 201711 395 Cao 2017 304 Sun 2015 I 304 Sun 2015 I 32 Ge 2018 32 Ge 2018 37 Tao 2015 I 37 Tao 2015 I	000000000000000000000000000000000000000	30 50 30 20	00011	50 30 20 20	0.7%	Not estimable Nat estimable 1.00 (0.07, 14.90) 3.00 (0.34, 26.45)	
302 Blan 201711 39F Cao 2017 39H Sun 2015 I 39H Sun 20151 32G 2018 9 Tao 20151 9 Tao 20151 9 W Cui 2015	0 0 1 3 0	30 50 30 20 20 30	00011	50 30 30 20 20 20	0.7% 0.7% 1.3%	Not estimable Nat estimable 1.00 (0.07, 14.90) 3.00 (0.34, 26.45) 0.23 (0.01, 5.26)	
xx2 Biax2017II 37 Cao 2017 394 Sun 2015 I 349 Sun 2015 I 324 Sun 2015 I 32 Gi 2018 Y Tao 2015 I Y Tao 2015 I 37 Yu 2015 I 25 Yu 2015 I	0001308	30 50 30 20 30 30 40	0001113	50 30 30 30 30 30 40	0.7% 0.7% 1.3% 2.5%	Not estimable Nat estimable 1.00 (0.07, 14.90) 0.00 (0.34, 26.45) 0.23 (0.01, 5.28) 0.14 (0.01, 2.60)	
xx2 Biax2017II 397 Cao 2017 394 Sun 2015 I 394 Sun 2015 I 394 Sun 2015 I 372 GL 2015 I 47 Tao 2015 I 47 Tao 2015 I 47 Tao 2015 I 297 Yu 2015 I 297 Yu 2015 I	0 0 1 3 0 8 1	30 50 30 20 30 30 30 40 40	00011133	50 30 30 30 30 40 40	0.7% 0.7% 1.3% 2.5% 2.1%	Not estimable Nat estimable 1.00 [0.07, 14.30] 3.00 [0.34, 26.45] 0.23 [0.01, 5.26] 0.14 [0.01, 2.60] 0.33 [0.04, 3.07]	
xx2 Biax201711 397 Cao 2017 394 Sun 2015 I 394 Sun 2015 I 325 GL 2016 V Tao 2015 I V Tao 2015 I VW Col 2015 297 Vu 2015 I 297 Vu 2015 I 297 Vu 2015 I 297 Vu 2015 II	0 0 1 3 0 8 1 3	30 50 30 20 30 40 40 40	000111333	50 30 20 20 20 40 40 40 40 40 40 40 40 40 40 40 40 40	0.7% 0.7% 1.3% 2.5% 2.1%	Not estimable Nat estimable 1.00 [0.07, 14.30] 0.00 [0.34, 26.45] 0.23 [0.01, 5.26] 0.33 [0.04, 3.07] 1.00 [0.21, 4.66]	
xx2 Biax201711 3x7 Cao 2017 3x4 Sun 2015 I 3x4 Sun 2015 I 3x2 Gi 2018 Y Tao 2015 I YY Tao 2015 I YW Cui 2015 25 Yu 2015 I 27 Yu 2015 II 27 Yu 2015 II 27 Yu 2015 II 27 Yu 2015 II	0 0 1 3 0 8 1 3 4	30 50 30 20 30 40 40 40	0001110000	5 3 3 3 3 3 3 4 4 4	0.7% 0.7% 1.3% 2.5% 2.1% 2.1%	Not estimable Nat estimable 1.00 [3:07, 14:303 3.00 [0:34, 26:45] 0:23 [5:01, 5:28] 0:14 [5:01, 2:60] 0:33 [5:04, 3:07] 1:00 [5:21, 4:66] 1:33 [5:22, 5:56]	
xx2 Biax2017II 3x7 Cao 2017 3x4 Bun 2015 I 3x4 Bun 2015 I 3x2 Gr 2018 Y Tao 2015 I Y Tao 2015 I YW Coi 2015 2x7 Yu 2015 I 2x7 Yu 2015 II 2x7 Yu 2015 II 2x7 Yu 2015 II 2x7 Yu 2015 II 2x7 Yu 2015 II	00013081342	30 50 50 30 20 30 30 40 40 40 25	000====0000==	55522224442	0.7% 0.7% 1.3% 2.5% 2.1% 2.1% 0.7%	Not estimable Not estimable 1.00 [0.07, 14.30] 0.03 [0.07, 14.30] 0.23 [0.01, 5.28] 0.14 [0.01, 2.04] 0.33 [0.04, 3.07] 1.00 [0.21, 4.46] 1.33 [0.22, 5.59] 2.00 [0.16, 20.67]	
xx2 Biax2017II xx7 Cao 2017 xx4 Sun 2015 I xx4 Sun 2015 I xx2 Gi 2010 y Tao 2015 I y Tao 2015 I y Tao 2015 I y Yu 2015 I ZF yu 2015 I ZF yu 2015 II ZF yu 2015 II Sufficient (05% CB) Yutao 2014	00017081742	10 50 50 20 20 20 20 30 40 40 40 25 641	0001111000	55 35 25 25 25 25 25 25 25 25 25 25 25 25 25	0.7% 0.7% 1.3% 2.5% 2.1% 2.1% 0.7% \$8.8%	Not extimable Nat estimable 1.00 [3:07, 14:30] 3.00 [0:34, 26:43] 0:33 [3:04, 3:07] 0:33 [3:04, 3:07] 1:00 [3:21, 4:66] 1:33 [3:25, 56] 2:00 [0:19, 20:67] 0:33 [0:48, 1.44]	
xiC Bian20178 37 Cao 2017 34 Gun 2015 I 34 Gun 2015 I 32 Gi 2018 Y Tao 20151 Y Tao 20151 Y Tao 20151 27 Yu 20151 27 Yu 20151 27 Yu 20158 27 Yu 20158 2	0 0 1 3 0 1 3 4 2 20 7.46, tf = 13	30 50 50 20 20 30 40 40 40 25 641	0 0 1 1 3 3 3 3 1 24 1 8), F= 0	55 55 55 55 55 55 55 55 55 55 55 55 55	0.7% 0.7% 1.3% 2.5% 2.1% 2.1% 0.7% 8.8%	Not extimable Nat estimable 1,00 (0,07,14.90) 3,00 (0,07,14.90) 0,23 (0,07,14.90) 0,23 (0,07,24.90) 0,33 (0,04,3.07) 1,00 (0,2),4.40 1,33 (0,04,3.07) 1,33 (0,2,5.50) 2,00 (0,19,20.67) 0,33 (0,48, 1,44)	
xiC Bian2017II 37 Cao 2017 34 Gun 2015 I 34 Gun 2015 I 32 Gi 2018 V Tao 2015 I V Tao 2015 I V Tao 2015 I VW Cui 2015 27 Vui 2015 I 27 Vui 2015 I 35 dubtora (95% Cl) Totai evento Hetarogenetic Chi ^a = Test for overall sifict	0 0 0 1 3 0 0 1 3 4 2 20 7.46, st = 11 7.46, st = 11 7.45, st = 10 7.45,	30 50 30 20 20 30 40 40 40 25 641 1 (P = 0.8 × 0.52)	0 0 1 1 3 3 3 3 1 24 1 8), (*= 0)	5 3 3 2 3 2 3 2 4 4 4 4 2 5 1 6 1	0.7% 0.7% 1.3% 2.1% 2.1% 0.7% \$8.0%	Not exismable Nat esismable 1.00 [0.07, 14.30] 3.00 [0.34, 26.45] 0.23 [0.07, 24.30] 0.33 [0.04, 3.07] 1.00 [0.21, 4.66] 1.33 [0.24, 4.66] 1.33 [0.32, 5.56] 2.00 [0.10, 20.67] 1.03 [0.48, 1.44]	
xiC Bian2017II 397 Cao 2017 394 Gun 2015 I 394 Gun 2015 I 394 Gun 2015 I 327 Gi 2018 Y Tao 2015 I Y Tao 2015 I Y Tao 2015 I 27 Yu 2015 I 27 Yu 2015 I 27 Yu 2015 II 27 YU 20 YU 2015 II 27 YU 2015 II 27 YU 2015 II 27 YU 2015 II	0 0 0 1 3 0 1 3 4 2 20 1 3 4 2 20 1 3 4 2 20 1 3 4 2 20 1 3 4 2 20 1 3 5 4 2 20 1 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	30 50 50 20 20 20 30 40 40 40 40 25 641 1(P = 0.1 * 0.52) 1923	0 0 1 1 3 3 3 3 1 3 1 2 4 1 2 4 1 2 4 1 2 4	10 30 20 20 20 40 40 40 20 20 40 40 20 20 40 40 20 20 40 40 40 20 20 40 40 40 20 20 40 40 40 40 40 40 40 40 40 40 40 40 40	0.7% 0.7% 1.3% 2.5% 2.1% 2.1% 0.7% 18.8%	Not existinable Nat estimable 1,00 (0,07,14.90) 3,00 (0,07,14.90) 0,23 (0,07,14.90) 0,23 (0,07,24,00) 0,33 (0,04,307) 1,00 (0,2),4.460 1,33 (0,2,5.56) 2,00 (0,19,20,67) 0,83 (0,48, 1,44) 0,85 (0,47, 0,79)	
xiC Bian2017II xiF Cao 2017 xiH Sun 2015 I xiH Sun 2015 I xiH Sun 2015 I y Tao 2015 I y Tao 2015 I y Tao 2015 I y Y Tao 2015 I ZF Yu 2015 I Total events Hetarogenetic Chi ^e = Test for overall effect	0 0 1 3 0 1 3 4 2 20 7.46, df = 11 2 = 0.85 (P-	30 50 50 20 20 30 40 40 40 40 40 25 641 1(P = 0.1 52) 1923	0 0 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	50 30 20 40 40 40 40 25 631 4893	0.7% 0.7% 1.2% 2.5% 2.1% 2.1% 0.7% 18.8%	Not extimable Nat estimable 1 00 [3 07, 14 30] 3 00 [3 34, 26 45] 0 14 [3 04, 3 07] 1 00 [3 27, 4 46] 0 33 [3 04, 3 07] 1 00 [3 27, 4 66] 1 33 [3 32, 5 56] 2 00 [0 19, 20.67] 6.83 [0.48, 1.44] 0.61 [0.47, 8.79]	•
xiC Bian2017II xiF Cao 2017 xiH Gun 2015 II xiH Gun 2015II xiZ Gl 2018 Y Tao 2015II YY Cao 2015 YY Cao 2015II YW Cai 2015II ZF Yu 2015II Total events Hetarogeneity: Chi ^e = Total (95% CB) Total events Hetarogeneity: Chi ^e =	0 0 0 1 3 3 4 20 7 46, th = 11 7 46, th = 11	30 50 50 30 20 20 30 40 40 40 40 25 641 9 (P = 0.1 25 641 9 (P = 0.1 25 7 1923 1923	0 0 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	50 50 50 50 50 50 50 50 50 50 50 50 50 5	0.7% 0.7% 1.3% 2.5% 2.1% 0.7% 18.0%	Not extimable Nat estimable 1.00 [0.07, 14.30] 0.00 [0.34, 26, 43] 0.33 [0.04, 3.07] 1.00 [0.21, 4.60] 0.33 [0.04, 3.07] 1.00 [0.21, 4.60] 1.33 [0.2, 5.60] 1.33 [0.46, 1.44] 0.61 [0.47, 0.79]	0.005 0.1 10 200





5. Conclusion

The results demonstrate that compared with sufentanil, PCA with hydromorphone is more effective in relieving postoperative pain at 12, 24, and 48 hours and reducing PCA request, and significantly decreases the incidence of postoperative adverse events. However, its effect on analgesia is not obvious. The quality of clinical studies is relatively low and the dosage in most studies is different; therefore, high-quality multicenter, randomized, parallel-controlled, and blind trials are needed for further study. The studies are of low quality and are all of Chinese origin, so this meta-analysis conclusion is only suitable for Chinese.

Author contributions

Conceptualization: Zhongbiao Nie, Bin Lu, Yao-yao Guo.

- Data curation: Zhongbiao Nie, Zhi-Hong Li, Bin Lu, Yao-yao Guo, Ran Zhang.
- Formal analysis: Zhongbiao Nie, Bin Lu.
- Methodology: Zhongbiao Nie, Zhi-Hong Li, Bin Lu, Ran Zhang.
- Software: Zhongbiao Nie, Zhi-Hong Li, Ran Zhang.
- Writing original draft: Zhongbiao Nie, Zhi-Hong Li, Ran Zhang.
- Writing review & editing: Zhongbiao Nie, Zhi-Hong Li, Ran Zhang.

References

- China Accelerated Rehabilitation Surgery Expert GroupExpert consensus on perioperative management of accelerated rehabilitation surgery in China. Chin J Surg 2016;54:413–8.
- [2] Chinese Medical Association Anesthesiology BranchExpert consensus on postoperative pain management in adults. J Clin Anesthesiol 2010; 26:190–6.

- [3] Georges P, Lavand'Homme P. Intrathecal hydromorphone instead of the old intrathecal morphine: the best is the enemy of the good. Eur J Anaesthesiol 2012;29:3–4.
- [4] Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Bri J Anaesthesia 2011;107:319–28.
- [5] Liu R, Hu XL, Yi H, et al. Clinical research progress of hydromorphone hydrochloride. Chin Prescription drugs 2014;29:119–21.
- [6] Xu LC. Pharmacological action and clinical research progress of hydrogen morphine. Chin J Pain Med 2015;21:701–3.
- [7] Gajarawala S, Wells A, Watkins E, et al. Intrathecal hydromorphone as an analgesia option for gynecology patients. JAAPA 2020;33:33–7.
- [8] Lu Xu, Li YH. Research progress in pharmacological action and clinical application of sufentanil. Anhui Med 2011;15:375–7.
- [9] Bhavsar R, Sloth E, Folkersen L, et al. Sufentanil preserves hemodynamics and left ventricular function in patients with ischemic heart disease. Acta Anaesthesiol Scandinavica 2011;55:1002–9.
- [10] Fechner J, Ihmsen H, Schüttler J, et al. The impact of intra-operative sufentanil dosing on post-operative pain, hyperalgesia and morphine consumption after cardiac surgery. Euro J Pain 2013;17:562–70.
- [11] Liu L, Li B, Cao Q, et al. Effects of additional intraoperative administration of sufentanil on postoperative pain, stress and inflammatory responses in patients undergoing laparoscopic myomectomy: a double-blind, randomized, placebo-controlled trial. J Pain Res 2020; 2187–95.
- [12] Miller RD, Cohen NH. Miller's anesthesia. Churchill Livingstone/ Elsevier, 2010.
- [13] Cochrane. Data collection form for intervention reviews: RCTs and non-RCTs. 3 edn. Cochrane Database of Systematic Reviews, 2014.
- [14] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Epidemiol Biostat Public Health 2009;6:e1–34.
- [15] Yu ZF, Guan J. Clinical study of hydromorphone hydrochloride in patient-controlled analgesia. Chin Med Guide 2015;108–9.
- [16] Liu LH, Jiang XJ, Dai M, et al. Analgesic effect of hydromorphone hydrochloride combined with levobupivacaine for lower limb bone surgery. Modern Practical Med 2015;27:1182–3.
- [17] Sun X, Liu B, Xinyou LI, et al. Efficacy of hydromorphone hydrochloride on patient-controlled intravenous analgesia after total hysterectomy. Shanghai Med Pharmaceut J 2015;38–40.

- [18] Cui YW, Lv HS, Zhang L, et al. Clinical observation of postoperative analgesia by hydrogen morphine in department of orthopedics. Chin J Clinic 2015;155–7.
- [19] Cao XF, Li Y, Liu GY, et al. Application of hydro morphine combined with flurbiprofen in postoperative analgesia after lower limb surgery in department of orthopedics. J Harbin Med Univ 2017;51:259–62.
- [20] Xin-zhu QI, An qiong M AO, et al. The effect of hydromorphone hydrochloride injection in intravenous self-controlled analgesia after laparoscopic subtotal hysterectomy. J Clin Med 2018;5:2.
- [21] Zhao ZY, Wang XX, Zhang R, et al. Effect of postoperative intravenous analgesia with hydrogen morphine and sufentanil on children with cerebral palsy. Sichuan Med 2014;1512–5.
- [22] Rui Han. Effect of hydromorphone hydrochloride on patient-controlled analgesia after cesarean section. Electron J Modern Med Health Res 2017;22:23.
- [23] Wang HG, Zahang YQ, Lin QH, et al. Clinical experience of intravenous morphine hydrochloride in patient-controlled intravenous analgesia after endoscopic sinus surgery. Chin J Otorhinolaryngol Skull Base Surg 2014;453–5.
- [24] Su MX, Hua Zhang, Li KL, et al. To investigate the clinical effect of hydromorphone combined with levobupivacaine in patient-controlled epidural analgesia after abdominal hysterectomy. Chin Pract Med 2018;13:2.
- [25] Yang FM. Comparison of the effects of morphine hydrochloride and sufentanil on patient-controlled intravenous analgesia after total hip arthroplasty in elderly patients. Jiangxi Med J 2016;51:582–4.

- [26] Bian XC, Xing-Guo XV, Huang XC, et al. Clinical effect of hydromorphone in postoperative patient-controlled intravenous analgesia after gynecological operation. Pract J Med Pharm 2017;34:3.
- [27] Tao Y, Yong YE, Wang N, et al. Clinical study on different dosages of hydromorphone for epidural analgesia in elderly patients with postoperative. Lab Med Clinic 2015;27:3006–8.
- [28] Higgins J, Green S. GSe, cochrane handbook for systematic reviews of interventions. Naunyn-Schmied ebergs Archiv für experimentelle Pathologie und Pharmakologie 2011;5:S38.
- [29] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
- [30] Chen BL. Clinical anesthetic pharmacology. Beijing: People, Medical Publishing House 2000;183–4.
- [31] Zheng H, Chen C, Guo SN, et al. Efficacy and safety of hydrogen morphine in postoperative analgesia in department of orthopedics. J Clin Surg 2016;24:68–70.
- [32] Liu S, Carpenter RL, Mulroy MF, et al. Intravenous versus epidural administration of hydromorphone. Effects on analgesia and recovery after radical retropubic prostatectomy. Anesthesiology 1995;82:682–8.
- [33] Zhen L, Li X, Gao X, et al. Dose determination of sufentanil for intravenous patient-controlled analgesia with background infusion in abdominal surgeries: a random study. PLoS One 2018;13:e0205959.
- [34] Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline. J Pain 2016;17:508–10.
- [35] Jonghe BD. Using and understanding sedation scoring systems: a systematic review. Intens Care Med 2000;26.